Legal & General Group’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-998
| Closed | -$53K | – | 3507 |
|
|
2020
Q3 | $53K | Sell |
998
-281
| -22% | -$17.3K | ﹤0.01% | 2681 |
|
|
2020
Q2 | $78K | Sell |
1,279
-19
| -1% | -$1.1K | ﹤0.01% | 2598 |
|
|
2020
Q1 | $71K | Sell |
1,298
-293
| -18% | -$16.7K | ﹤0.01% | 2502 |
|
|
2019
Q4 | $91K | Buy |
1,591
+242
| +18% | +$12.8K | ﹤0.01% | 2625 |
|
|
2019
Q3 | $72K | Hold |
1,349
| – | – | ﹤0.01% | 2625 |
|
|
2019
Q2 | $81K | Buy |
1,349
+138
| +11% | +$8.68K | ﹤0.01% | 2602 |
|
|
2019
Q1 | $75K | Hold |
1,211
| – | – | ﹤0.01% | 2582 |
|
|
2018
Q4 | $74K | Buy |
1,211
+404
| +50% | +$24.1K | ﹤0.01% | 2551 |
|
|
2018
Q3 | $47K | Sell |
807
-138
| -15% | -$7.04K | ﹤0.01% | 2802 |
|
|
2018
Q2 | $42K | Buy |
945
+19
| +2% | +$817 | ﹤0.01% | 2838 |
|
|
2018
Q1 | $41K | Sell |
926
-464
| -33% | -$19.5K | ﹤0.01% | 2847 |
|
|
2017
Q4 | $60K | Sell |
1,390
-207
| -13% | -$9.3K | ﹤0.01% | 2812 |
|
|
2017
Q3 | $75K | Buy |
1,597
+39
| +3% | +$1.87K | ﹤0.01% | 2775 |
|
|
2017
Q2 | $77K | Hold |
1,558
| – | – | ﹤0.01% | 2742 |
|
|
2017
Q1 | $84K | Hold |
1,558
| – | – | ﹤0.01% | 2644 |
|
|
2016
Q4 | $86K | Buy |
1,558
+742
| +91% | +$35.7K | ﹤0.01% | 2663 |
|
|
2016
Q3 | $37K | Sell |
816
-1,371
| -63% | -$55.1K | ﹤0.01% | 2661 |
|
|
2016
Q2 | $86K | Buy |
+2,187
| New | +$80.1K | ﹤0.01% | 2184 |
|
Other funds holding BSTC
Legal & General Group's BSTC Position: Q4 2020 in Review
Legal & General Group sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 998 shares — an estimated $53K sold.
Legal & General Group first reported a position in BSTC in Q2 2016 and held it in 18 quarters. The position peaked at $91K in Q4 2019. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Legal & General Group reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Legal & General Group sold 998 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $53K.
- Legal & General Group first reported a position in BioSpecifics Technologies Corp. in Q2 2016 and held it in 18 quarters.
- Legal & General Group's BioSpecifics Technologies Corp. position peaked at $91K in Q4 2019.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Legal & General Group's 13F filing for Q4 2020, filed 12 Feb 2021.